Adjuvant PD-1 inhibitors improve recurrence and survival outcomes in high-risk hepatocellular carcinoma patients after curative hepatectomy
The administration of adjuvant PD-1 inhibitors may effectively reduce the risk of tumor recurrence and improve survival in HCC patients with high risk of recurrence after curative hepatectomy.
Authors
- Zunyi Zhang
- Zhiwei Zhang (ORCID: https://orcid.org/0009-0007-2360-7576)
- Xizhong Shen (ORCID: https://orcid.org/0000-0003-3748-0709)
- Wei Yan (ORCID: https://orcid.org/0000-0002-5405-3189)
- Erlei Zhang (ORCID: https://orcid.org/0000-0002-7251-0275)
- Hanhua Dong
Institutions
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2025-03-22
- DOI
- https://doi.org/10.1186/s40001-025-02444-3
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32